Technical Analysis for KYKOF - Kyowa Hakko Kogyo

Grade Last Price % Change Price Change
grade A 21.65 1.50% 0.3200
KYKOF closed up 1.5 percent on Wednesday, December 4, 2019, on 3 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical KYKOF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Crossed Above 20 DMA Bullish 1.50%
MACD Bullish Signal Line Cross Bullish 1.50%
Narrow Range Bar Range Contraction 1.50%
BB Squeeze Ended Range Expansion 1.50%

Older signals for KYKOF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Kyowa Hakko Kirin Co., Ltd., a research and development-based life sciences company, manufactures and markets pharmaceuticals and bio-chemicals worldwide. Its products include ABSTRAL, a novel sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; and REGPARA, a new class of agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment for nausea and vomiting. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Medicine Biotechnology Cancer Pharmaceuticals Biology Chemotherapy Hypertension Allergies Vomiting Amgen Constipation Nausea Acute Lymphoblastic Leukemia Angina Pectoris Cytokines Erythropoiesis Stimulating Agent Growth Factors Secondary Hyperparathyroidism Erythropoietin Kirin Bio Chemicals Kirin Holdings Kyowa Hakko Kirin

Is KYKOF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Recent News
Indicators
Indicator Value
52 Week High 22.5
52 Week Low 13.25
Average Volume 6,638
200-Day Moving Average 17.4863
50-Day Moving Average 18.3024
20-Day Moving Average 19.1195
10-Day Moving Average 19.035
Average True Range 0.608
ADX 20.71
+DI 54.1705
-DI 34.1169
Chandelier Exit (Long, 3 ATRs ) 19.826
Chandelier Exit (Short, 3 ATRs ) 17.424
Upper Bollinger Band 21.1839
Lower Bollinger Band 17.0551
Percent B (%b) 1.11
BandWidth 21.594707
MACD Line 0.5038
MACD Signal Line 0.2307
MACD Histogram 0.2731
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.6500
Resistance 3 (R3) 21.6500 21.6500 21.6500
Resistance 2 (R2) 21.6500 21.6500 21.6500 21.6500
Resistance 1 (R1) 21.6500 21.6500 21.6500 21.6500 21.6500
Pivot Point 21.6500 21.6500 21.6500 21.6500 21.6500
Support 1 (S1) 21.6500 21.6500 21.6500 21.6500 21.6500
Support 2 (S2) 21.6500 21.6500 21.6500 21.6500
Support 3 (S3) 21.6500 21.6500 21.6500
Support 4 (S4) 21.6500